<DOC>
	<DOCNO>NCT00586573</DOCNO>
	<brief_summary>The primary objective study assess efficacy tolerability 12-week trial memantine hydrochloride administer twice daily 20 adult ( age 18-55 ) ADHD ADHD NOS . Improvement define : 1 ) change baseline investigator-rated DSM-IV base ADHD Rating Scale ; 2 ) change baseline questionnaire aim assess executive function ( BRIEF ) ; 3 ) change screen computerized neuropsychological battery ( CANTAB ) . We hypothesize memantine hydrochloride associate improve ADHD symptom associate deficit executive function . We also expect memantine well-tolerated predictable adverse event .</brief_summary>
	<brief_title>Open-Label Pilot Study Namenda Adult Subjects With ADHD ADHD NOS</brief_title>
	<detailed_description>Memantine ( Namenda ) low-affinity N-methyl-D-aspartate ( NMDA ) receptor antagonist believe work block prolonged low-level activation NMDA receptor resultant neuronal damage cause abnormal glutamatergic activity , yet also allow normal physiological activity NMDA channel . Memantine ( Namenda ) approve U.S. Food Drug Administration 2003 treatment moderate severe Alzheimer 's disease . Memantine improve delay decline cognition ( attention , language , visuo-spatial ability ) , well functional behavioral symptom adult moderate Alzheimer 's disease . Although efficacy safety memantine test people ADHD , spectrum disorder possibly amenable NMDA receptor antagonist treatment may include ADHD associated executive function deficit ( EFDs ) . To end , propose open-label pilot study memantine adult subject ADHD ADHD Not Otherwise Specified ( NOS ) . This 12-week , open-label pilot study assess efficacy tolerability memantine hydrochloride ( Namenda ) administer 20 adult 18-55 year age ADHD ADHD NOS . All subject enter study undergo standard screen diagnostic procedure . After obtain write informed consent subject , diagnosis ADHD establish clinical evaluation expert clinician . Only consent subject satisfy inclusion exclusion criterion include study .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>1 . Male female outpatient 1855 year age 2 . Subjects diagnosis Attention Deficit Hyperactivity Disorder ( ADHD ) , DSMIV ADHD NOS ( late onset ; &gt; 7 year ) , manifest clinical evaluation confirm structured interview . 3 . Subjects must score least 14 inattentive symptom question DSMIV base ADHD Rating Scale . 4 . Subjects ADHD specific CGI Severity score 4 ( &gt; moderately impair ) . 1 . Subjects medical condition treatment either jeopardize subject safety affect scientific merit study , include : 2 . History Renal Hepatic Impairment . 3 . Organic brain disorder . 4 . History Seizure disorder . 5 . Any clinically unstable psychiatric condition include follow : psychosis , suicidality , bipolar disorder , current substance use disorder ( alcohol drug ) current tic disorder . 6 . Mental retardation ( IQ &lt; 75 ) . 7 . Pregnant nursing female . 8 . Known hypersensitivity memantine . 9 . Any current psychotropic treatment , exception stable regimen SSRIs .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>ADHD</keyword>
	<keyword>Namenda</keyword>
</DOC>